OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
The ever-expanding landscape of antibody-drug conjugates (ADCs) in solid tumors: A systematic review
Panagiotis Filis, Ioannis Zerdes, Theodora Soumala, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 192, pp. 104189-104189
Open Access | Times Cited: 8
Panagiotis Filis, Ioannis Zerdes, Theodora Soumala, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 192, pp. 104189-104189
Open Access | Times Cited: 8
Showing 8 citing articles:
Biomarkers for Antibody–Drug Conjugates in Solid Tumors
Jalissa Katrini, Laura Boldrini, Celeste Santoro, et al.
Molecular Cancer Therapeutics (2024) Vol. 23, Iss. 4, pp. 436-446
Closed Access | Times Cited: 7
Jalissa Katrini, Laura Boldrini, Celeste Santoro, et al.
Molecular Cancer Therapeutics (2024) Vol. 23, Iss. 4, pp. 436-446
Closed Access | Times Cited: 7
Assessment of targets of antibody drug conjugates in SCLC
Abhishek Ajay, Han Wang, Ali Reza Rezvani, et al.
npj Precision Oncology (2025) Vol. 9, Iss. 1
Open Access
Abhishek Ajay, Han Wang, Ali Reza Rezvani, et al.
npj Precision Oncology (2025) Vol. 9, Iss. 1
Open Access
Global research progress in antibody-drug conjugates for solid tumors: Bibliometrics and visualized analysis
Wenjun Fang, Xueqing Ma, Ben Liu
Human Vaccines & Immunotherapeutics (2025) Vol. 21, Iss. 1
Open Access
Wenjun Fang, Xueqing Ma, Ben Liu
Human Vaccines & Immunotherapeutics (2025) Vol. 21, Iss. 1
Open Access
Nausea and vomiting in an evolving anticancer treatment landscape: long-delayed and emetogenic antibody-drug conjugates
Winnie Yeo, Giampaolo Bianchini, Javier Cortés, et al.
Future Oncology (2025), pp. 1-12
Open Access
Winnie Yeo, Giampaolo Bianchini, Javier Cortés, et al.
Future Oncology (2025), pp. 1-12
Open Access
Antibody-drug conjugate combinations in cancer treatment: clinical efficacy and clinical study perspectives
X. Shi, Kai Tang, Quanbin Zhang, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
X. Shi, Kai Tang, Quanbin Zhang, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Comparison of structural characteristics and anti-tumor activity of two alkali extracted peach gum arabinogalactan
Keyao Dai, Wenjie Ding, Zhen-tong Li, et al.
International Journal of Biological Macromolecules (2024) Vol. 279, pp. 135407-135407
Closed Access | Times Cited: 2
Keyao Dai, Wenjie Ding, Zhen-tong Li, et al.
International Journal of Biological Macromolecules (2024) Vol. 279, pp. 135407-135407
Closed Access | Times Cited: 2
IMT030122, A novel engineered EpCAM/CD3/4-1BB tri-specific antibody, enhances T-cell recruitment and demonstrates anti-tumor activity in mouse models of colorectal cancer
Jianbo Shen, Niliang Qian, Guili Xu, et al.
International Immunopharmacology (2024) Vol. 137, pp. 112424-112424
Closed Access | Times Cited: 1
Jianbo Shen, Niliang Qian, Guili Xu, et al.
International Immunopharmacology (2024) Vol. 137, pp. 112424-112424
Closed Access | Times Cited: 1
Real-world application of disitamab vedotin (RC48-ADC) in patients with breast cancer with different HER2 expression levels: efficacy and safety analysis
Ke Wang, Ting Xu, Kaichun Wu, et al.
The Oncologist (2024)
Open Access
Ke Wang, Ting Xu, Kaichun Wu, et al.
The Oncologist (2024)
Open Access
